Disrupting a single gene could improve CAR T cell immunotherapy, new study shows
CAR T cell therapy, a powerful type of immunotherapy, has begun to revolutionize cancer treatment. Pioneered at Memorial Sloan Kettering Cancer Center (MSK), the therapy involves engineering a patient’s T cells so they recognize and attack cancer cells. These CAR (chimeric antigen receptor) T cells are then multiplied in a lab and given back to the patient to be a continual fighting force against the cancer.
New research from the lab of physician-scientist Michel Sadelain, MD, PhD, shows that disrupting a single ...










